SECUADO
Peakasenapine
NDATRANSDERMALSYSTEM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
SECUADO (asenapine) is 12. First approved in 2019.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SECUADO (asenapine) is an atypical antipsychotic administered via transdermal patch for bipolar I disorder. The mechanism of action in bipolar disorder remains unknown, but asenapine exhibits broad receptor antagonism across serotonin, dopamine, adrenergic, and histamine systems. The transdermal formulation offers an alternative to sublingual administration with improved patient adherence potential.
$0.005BPart D
Peak7.2 years to LOEProduct is at peak lifecycle with modest Part D penetration (~3,700 claims in 2023), indicating niche market positioning with limited near-term team expansion.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of asenapine in bipolar I disorder is unknown. 12.2 Pharmacodynamics Asenapine exhibits high affinity for serotonin 5-HT 1A , 5-HT 1B , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 5A , 5-HT 6 , and 5-HT 7 receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03,…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.